Market closed
Jasper Therapeutics/$JSPR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Jasper Therapeutics
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
Ticker
$JSPR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
64
Website
JSPR Metrics
BasicAdvanced
$71M
-
-$4.89
2.24
-
Price and volume
Market cap
$71M
Beta
2.24
52-week high
$26.84
52-week low
$3.13
Average daily volume
177K
Financial strength
Current ratio
4.975
Quick ratio
4.702
Long term debt to equity
1.174
Total debt to equity
2.94
Management effectiveness
Return on assets (TTM)
-54.52%
Return on equity (TTM)
-101.73%
Valuation
Price to book
1.15
Price to tangible book (TTM)
1.15
Price to free cash flow (TTM)
-1.095
Growth
Earnings per share change (TTM)
-20.87%
3-year earnings per share growth (CAGR)
-43.36%
What the Analysts think about JSPR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Jasper Therapeutics stock.
JSPR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
JSPR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
JSPR News
AllArticlesVideos
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
GlobeNewsWire·2 months ago
Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting
GlobeNewsWire·2 months ago
Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Jasper Therapeutics stock?
Jasper Therapeutics (JSPR) has a market cap of $71M as of May 08, 2025.
What is the P/E ratio for Jasper Therapeutics stock?
The price to earnings (P/E) ratio for Jasper Therapeutics (JSPR) stock is 0 as of May 08, 2025.
Does Jasper Therapeutics stock pay dividends?
No, Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders as of May 08, 2025.
When is the next Jasper Therapeutics dividend payment date?
Jasper Therapeutics (JSPR) stock does not pay dividends to its shareholders.
What is the beta indicator for Jasper Therapeutics?
Jasper Therapeutics (JSPR) has a beta rating of 2.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.